Revolutionizing Therapeutic Protein Selection

Our latest innovation, a cutting-edge in vitro platform, is set to transform the landscape of therapeutic protein selection.. With its high sensitivity, throughput, and multiplexing capability, this bioassay empowers researchers to make informed decisions during the drug development process.

Accelerate PD-1/PD-L1 Inhibitor Discovery

we offer an in vitro assay that can quickly, easily, and accurately detect potential drug candidates. Our assay helps you to identify candidate compounds, including antibodies, VHHs (Nanobody), and other peptides, that effectively bind to the target molecule. We help you to optimize your drug development process, reducing both time and cost while delivering a superior final product.

Learn more

Accelerate (VHH) Nanobody Discovery and Selection

Our in vitro platform has been developed to expedite the selection of novel binders with high specificity and strong affinity for a target molecule of interest. This platform offers a rapid and efficient solution for researchers and pharmaceutical companies, facilitating the discovery of potential drug candidates with precise binding characteristics.

LEARN MORE

Our protocols are user-friendly and can be adapted to diverse research questions, making them easily implementable in a wide range of experiments. Target molecule are detected in a three-step process. The technology requires minimal preparation and provides results in hours instead of days compared to other identification methods.

Discovering Precision Binders at Lightning Speed!

At SYG BIOTECH, we're pioneering the future of biotechnological solutions with a relentless commitment to enhancing health outcomes globally. Our latest innovation, a cutting-edge in vitro platform, is set to transform the landscape of therapeutic protein selection.
Our state-of-the-art platform accelerates the discovery and development of new therapeutic proteins, including VHHs, DARPINs, and other peptides. These proteins are engineered to precisely target immune checkpoints such as PD-1/PD-L1, pivotal in treating various diseases, especially in oncology by inhibiting these checkpoints. Our products can play a crucial role in cancer therapies, potentially turning the tide against this global challenge.
Alongside our therapeutic protein selection platform, we have developed an innovative rapid detection kit for PD-1 and PD-L1, as well as their inhibitors. This user-friendly kit enables researchers to detect and analyze these biomarkers with unprecedented speed and accuracy. Our technology not only facilitates the rapid development of personalized and effective therapies but also empowers the scientific community to push forward the boundaries of what's possible in medical science.

Why choose us?

Assessing the interaction of a specific ligand with its target protein often involves expensive, time-consuming, and labor-intensive methods that require specialized equipment and expertise. In contrast, our method provides a cost-effective and user-friendly alternative to the traditional techniques. Protocols can be adapted to a wide range of research questions.

EASY-TO-USE

Our assay are easy to prepare, and familiar handling. Anyone can do it and get results in 3 simple steps

RAPID

The assay requires minimal preparation and provides results in hours (3 hours) instead of days compared to other identification methods.

Instrument free

Accessible to any standard biology lab.

COST-EFFECTIVE

Our method provides a cost-effective and user-friendly alternative to the traditional techniques

Precision

Adaptable to the specific detection of any protein and compatible with complex samples and suitable for small sample volumes.

Customisable

Protocols is highly flexible and can be tailored to measure various protein-protein interactions.

You would like to have access to this exciting technology?

Join us as we set new standards in biotechnology and unlock the potential of personalized medicine.

Get in touch